What is ImmunityBio, Inc.'s fair value adjustment of warrants?

ImmunityBio, Inc. (IBRX) reported fair value adjustment of warrants of $295.41M in Q1 2026.

How has ImmunityBio, Inc.'s fair value adjustment of warrants changed year-over-year?

ImmunityBio, Inc.'s fair value adjustment of warrants increased by 65840.4% year-over-year, from $448K to $295.41M.

What does fair value adjustment of warrants mean?

This metric tracks the non-cash changes in the fair value of warrants issued by the company, which are accounted for as liabilities. These adjustments reflect the market's assessment of the company's equity value and volatility, impacting the reported net income without affecting cash.

ImmunityBio, Inc. IBRX Fair Value Adjustment Of Warrants

Fair Value Adjustment Of Warrants at other companies

Rigetti Computing, Inc.RGTI

-$53.7M-0.8%

ToastTOST

-$8M-167%

Cipher Digital, Inc. CIFR

-$43.61M—

ImmunityBio, Inc.IBRX

$295.41M+65,840%

Tempus AI, Inc.TEM

$0—

Revolution Medicines, Inc.RVMD

$15.79M+747%

Segments

By segment

See full

Reportable Segment$295.41M+65,840%

Other financials

Income statement

See full

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

See full

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

See full

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation

See full

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

See full

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

See full

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FairValueAdjustmentOfWarrants.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s fair value adjustment of warrants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ImmunityBio, Inc.'s fair value adjustment of warrants?: ImmunityBio, Inc. (IBRX) reported fair value adjustment of warrants of $295.41M in Q1 2026.
How has ImmunityBio, Inc.'s fair value adjustment of warrants changed year-over-year?: ImmunityBio, Inc.'s fair value adjustment of warrants increased by 65840.4% year-over-year, from $448K to $295.41M.
What does fair value adjustment of warrants mean?: This metric tracks the non-cash changes in the fair value of warrants issued by the company, which are accounted for as liabilities. These adjustments reflect the market's assessment of the company's equity value and volatility, impacting the reported net income without affecting cash.